T rkischer Arzneimittelmarkt boomt

Article Abstract:

In 1997, Turkish pharmaceutical companies recorded double-digit growth rates in sales and turnover. Imports of medicines and pharmaceutical raw materials to Turkey increased by more than one third to US$ 1.2bn. The growth is expected to continue at a high level. In 1997, the Turks spent about US$ 27 per person on medicines. Total private consumption of medicines is estimated at US$ 1.73bn (US$ 1.57bn). State-owned health institutions bought medicines for US$ 400mn and other public institutions for US$ 200mn. By 2000, the private market is expected to grow to US$ 2.5bn. Annual investments of US$ 100mn would be required to meet the growing demand with domestic production. This is why foreign companies, such as Boehringer Ingelheim or US firms, want to gain foothold in Turkey. Imports are expected to increase from 1999 when a new patent law comes into force. The new patent regulations are to increase the costs of Turkish producers. Duties on EU imports are to be abolished. Local pharmaceutical companies are trying to prevent the passing of the new law.

Comment:

Turkey: Pharmaceutical companies recorded double-digit growth rates in sales and turnover in 1997

Sales & consumption, Turkey

---

Slowakische Chemie w chst um 2% pro Jahr

Article Abstract:

The Slovak ministry of economics expects the country's chemical and pharmaceutical industry to grow by 1.9-2.5% annually until the year 2005. In 1997 the manufacturing output of the chemical and pharmaceutical industry grew from Sk 90.73bn to Sk 94.35bn, which is 19.6% of the total Slovak industrial output. Exports are expected to grow by 2.7-3.3% from Sk 59bn (27.1% of total Slovak exports) in 1997. However, restructuring and modernisation measures are necessary to strengthen the industry's international competitiveness. In 1997 Sk 13.6bn was invested in the chemical industry, of which 70% in machinery and equipment. 75% of this was imported. The most promising segments are said to be chemical fibres, plastics, bitumen, adhesives, rubber products, organic chemicals and mineral fertiliser. The main export market so far is Czechia, while exports to the EU increased and sales to Russia were static.

Comment:

Slovakia: Ministry of economics expects country's chemical & pharmaceutical industry to grow by 1.9-2.5% annually until yr 2005

Market information - general, Slovakia

---

GERMANY/NL: PURAC, BOEHRINGER REVISE DEAL

Article Abstract:

Purac Biochem BV of Gorinchem, the world's biggest producer of natural lactic acid and derivatives, has revised its cooperation agreement with Boehringer Ingelheim Pharma KG concerning the marketing of lactic acid in Germany. From 1 October 1999 the marketing of lactic acid to the food and cosmetics industries and for chemical-technical applications in Germany will be transferred from Boehringer to Bingen-based Purac Deutschland GmbH. Boehringer will continue to market the lactic acid to the pharmaceutical industry.

Germany, Vitamin, Nutrient & Hematinic Preps, Food Additives, All Other Basic Organic Chemical Manufacturing, Strategic alliances, Flavor & Perfume Materials, Additives, Boehringer Ingelheim Pharma KG, PURAC BIOCHEM BV

Similar abstracts:

• Abstracts: A model system to study the insertion of cholesterol into a phospholipid monolayer. Effects of cholesterol on the properties of phospholipid membranes. 3. Local lateral structure
• Abstracts: Competitive hydrolytic and elimination mechanisms in the urease catalyzed decomposition of urea. Theoretical calculations of refractive indices and optical effects in spectra of nitric acid and nitric acid monohydrate crystals
• Abstracts: Clariant cuts again as costs erode margin. Latex platforms for new market needs at lower costs. James Robinson moves to new HQ
• Abstracts: Polymorphism - necessary evil or great opportunity? Meeting the challenge of colour
• Abstracts: Diffuse transmittance spectroscopy of diatomic Ag nuclei on AgBr microcrystals

This website is not affiliated with document authors or copyright owners. This page is provided for informational purposes only. Unintentional errors are possible.